PTC THERAPEUTICS INC (PTCT)

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 19, 2024, the company approved non-statutory stock options to purchase an...

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin MAA to the European Medicines Agency. The MAA...

PTC Therapeutics Provides Key Regulatory Updates

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza™ (eladocagene exuparvovec), a gene...

PTC Therapeutics Breaks Above 200-Day Moving Average - Bullish for PTCT

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

/PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending...

Notable earnings after Thursday's close

Major earnings expected after the bell on Thursday include:Zscaler (ZS)Hewlett Packard Enterprise Company (HPE)Dell Technologies (DELL)Autodesk (ADSK)Veeva...

PTC Therapeutics to Participate at Upcoming Investor Conferences

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: TD Cowen...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Feb. 15, 2024, the company approved non-statutory stock options to purchase an...

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and...

Notable Tuesday Option Activity: DIN, PTCT, TOL

Biogen gets EU approval for Friedrich's ataxia drug (NASDAQ:BIIB)

Biogen (BIIB) said it has received EU approval for its drug Skyclarys for the treatment of Friedreich’s ataxia, or FA, in patients aged 16 years and older. Read more here.

1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?

Bad news for one player does not always equal good news for another.

Noteworthy Friday Option Activity: UTI, HUN, PTCT

PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug

European regulators will likely force PTC Therapeutics to pull its drug, Translarna, from the market.

PTC Therapeutics down 10% as EMA issues Translarna negative opinion (NASDAQ:PTCT)

The European Medicines Agency's negative opinion on PTC Therapeutics' Translarna will result in the withdrawal of the treatment. Read more here.

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 42nd Annual J.P. Morgan...

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 42nd Annual J.P. Morgan...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 10, 2023, the company approved non-statutory stock options to purchase an...

Commit To Purchase PTC Therapeutics At $28, Earn 63.1% Annualized Using Options

PTC Therapeutics issues EU, US regulatory updates on Translarna (PTCT)

PTC Therapeutics (PTCT) has issued an update on its efforts to renew conditional approval for its drug Translarna in the EU and file for FDA approval in the US. Read more here.

PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States....

Notable Tuesday Option Activity: OLLI, PUBM, PTCT

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 1, 2023, the company approved non-statutory stock options to purchase an...

ALGN Stock Alert: Align Technology Announces $250M Stock Buyback Program

Align Technology stock is rising on Friday after the company announced plans to repurchase $250 million worth of ALGN shares.

PTC Therapeutics stock slides after Citi downgrades to Sell (NASDAQ:PTCT)

PTC Therapeutics (PTCT) plunges ~22% premarket on Friday after the Citi downgrade

RBLX Stock Alert: Analysts Are Pounding the Table on Roblox

Roblox stock is rising higher on Friday after analysts upgraded shares of RBLX and increased price targets for the gaming company.

Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?

PTC Therapeutics stock is falling on Friday as PTCT investors react to the company's lackluster earnings report for Q3 2023.